GNLX

#3227
Genelux Corporation Common Stock
2.98
+4.56%
版块:
基础:
利润货币:
日范围
2.98
2.98
年范围
1.99
8.54
日变化
+4.56%
每月变动
+2.05%
6个月变化
-19.46%
年变化
-31.18%
前一天收盘价
2.85
Open
2.98
Bid
Ask
Low
2.98
High
2.98
交易量
7
Open full chart

Financials

Overview 声明 Statistics Dividends
Quarterly Annual
Income statement Balance sheet Cash flow
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

新闻